Results 111 to 120 of about 12,493 (244)

Cough due to ace inhibitors: A case control study using automated general practice data [PDF]

, 1996
Objectives: To determine the risk of coughing as an adverse reaction to ACE inhibitors under everyday circumstances in a large population, and to study whether this adverse effect was duration or dose dependent.
Lei, J. (Johan) van der, Stricker, B.H.Ch. (Bruno), Visser, L.E. (Loes), Vlug, A.E. (Albert)   +3 more
core   +1 more source

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data

Therapeutics and Clinical Risk Management, 2012
Gary Bloomgren, Bjørn Sperling, Kimberly Cushing, Madé WentenBiogen Idec Inc., Weston, MA, USABackground: Intramuscular interferon beta-1a (IFNβ-1a), a multiple sclerosis (MS) therapy that has been commercially available ...
Bloomgren G, Sperling B, Cushing K, Wenten M   +3 more
doaj  

The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi.

, 2005
BACKGROUND: The proportion of cases of tuberculosis due to recent infection can be estimated in long-term population-based studies using molecular techniques.
Crampin, Amelia C, Drobniewski, Francis, Fine, Paul EM, Glynn, Judith R, Mwaungulu, Frank D, Ndlovu, Richard, Ngwira, Bagrey M, Traore, Hamidou, Yates, Malcolm D   +8 more
core   +1 more source

Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real‐world practice in Korea: A prospective, observational, multi‐center, postmarketing surveillance study

, 2021
Sang Woong Youn, Dae Young Yu, Byung‐Soo Kim, Youngdoe Kim, Kwang Joong Kim, Jee‐Ho Choi, Sang Wook Son, Eun‐So Lee, Young Suck Ro, Young Lip Park, YoungJa Lee, Jeung Hoon Lee, Hyun Jeong Park, Tae‐Yoon Kim, Min‐Geol Lee, Min Kyung Shin, Gwang Seong Choi, Dong Hyun Kim, Seong Jin Jo, Seung Chul Lee, the Stelara PMS investigators   +20 more
openalex   +2 more sources

Threshold Size of Medical Tablets and Capsules: Based on Information Collected by Japanese Medical Wholesaler

Patient Preference and Adherence, 2020
Kenji Kabeya,1 Hiroki Satoh,2,3 Satoko Hori,4 Yasumasa Miura,5 Yasufumi Sawada2 1Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan; 2Laboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The ...
Kabeya K, Satoh H, Hori S, Miura Y, Sawada Y   +4 more
doaj  

Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy [PDF]

, 2016
In a Perspective, Lucy Chappell and Anna David discuss ways to develop and test pharmacological treatments in ...
Chappell, LC, David, AL
core  

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies [PDF]

, 2015
Thomas J. Humphries, Stephan Rauchensteiner, Claudia Tückmantel, Alexander Pieper, Monika Maas Enriquez, Prasad Mathew   +5 more
openalex   +1 more source

Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. [PDF]

, 1992
D G Colin‐Jones, M. J. S. Langman, D. H. Lawson, RF Logan, K. R. Paterson, M P Vessey   +5 more
openalex   +1 more source

Overview of global monitoring systems for the side effects and adverse events associated with medicinal cannabis use: a scoping review using a systematic approach

BMJ Open
Objectives The use of cannabis-based medicine (CBM) as a therapeutic has surged in Australia over the past 5 years. Historically, the United Nations Single Convention on Narcotic Drugs (1961) prohibited cannabis use in Europe, the USA, the UK and ...
Christine Mary Hallinan, Yvonne Ann Bonomo, Rebecca Qi Wang   +2 more
doaj   +1 more source

A Critical Examination of the FDA’s Efforts to Preempt Failure-to-Warn Claims [PDF]

, 2007
This article explores the legality and wisdom of the FDA’s effort to persuade courts to find most failure-to-warn claims preempted. The article first analyzes the FDA’s justifications for reversing its long-held views to the contrary and explains why ...
Kessler, David A., Vladeck, David C.
core   +1 more source